AI in Medicare Prior Authorization: Regulatory Shifts and Industry Accountability

The Centers for Medicare & Medicaid Services (CMS) is currently recalibrating its oversight of prior authorization, an administrative process that requires healthcare providers to obtain insurance approval before performing certain procedures or prescribing specific medications. As the agency integrates AI-driven models into original Medicare, it faces mounting pressure from lawmakers and patient advocates to curb potential abuses, particularly regarding how automated systems influence care denials.

CMS Oversight and the WISeR Model

The federal government is testing new ground with the WISeR model, an initiative that utilizes AI to manage prior authorization requests. Under this framework, participating vendors are eligible to earn a portion of “averted expenditures”—a financial structure that has drawn scrutiny from critics who argue it creates a perverse incentive to deny medically necessary care to lower costs. Several members of Congress have introduced amendments and resolutions aimed at blocking funding for the model, citing significant risks to patient access and the potential for systemic bias against beneficiaries.

Regulatory Pressure on Medicare Advantage Plans

While CMS expands the use of AI within original Medicare, the agency is simultaneously pursuing stricter regulations for private Medicare Advantage (MA) plans. CMS leadership has signaled that insurance companies must streamline their prior authorization processes to reduce the burden on both patients and providers. Officials have indicated that if private insurers fail to implement these improvements voluntarily, the federal government will intervene with mandatory regulatory requirements to ensure patient access is not unfairly restricted.

Industry Response and Data Transparency

In an effort to preempt federal mandates, health insurance trade groups have begun releasing data regarding their administrative practices. According to an industry-based survey covering the period from June 2025 to April 2026, the volume of prior authorization requests declined by 11 percent. However, this data does not clarify whether the rate of claim denials has shifted, leaving a gap in understanding how automated systems are impacting patient outcomes.

To address concerns regarding algorithmic transparency, health plans responding to recent industry surveys have committed to specific standards. These organizations stated that AI and automated algorithms are not used to deny requests involving clinical necessity without a human clinician’s review. Insurers have also pledged to provide greater clarity regarding the clinical reasoning behind their automated decision-making processes.

The Debate Over Healthcare Automation

Despite industry assurances, the rapid adoption of AI in healthcare remains controversial. Critics argue that the current trajectory of healthcare technology prioritizes speed and cost-cutting over clinical outcomes. Dr. Jared Dashevsky, a physician and founder of the platform Healthcare Huddle, has characterized the trend as an “arms race to deny faster and appeal faster.” According to Dashevsky, while AI holds the potential to reduce administrative waste and improve the patient experience, the current implementation of these tools often serves to further automate a system that many providers view as fundamentally flawed.

Key Takeaways

• Regulatory Conflict: CMS is simultaneously deploying AI for original Medicare while threatening to regulate its use by private Medicare Advantage plans.
• Incentive Structures: The WISeR model’s focus on “averted expenditures” faces legislative opposition due to fears that it incentivizes care denials.
• Performance Reporting: Industry data indicates an 11 percent decrease in prior authorization requests between 2025 and 2026, though denial rates remain unverified by independent oversight.
• Clinical Oversight: Health plans have publicly committed to ensuring human clinician review for all denials involving medical necessity.

As the integration of AI in clinical decision-making evolves, the tension between administrative efficiency and patient advocacy will likely remain a central theme in federal healthcare policy. The focus for regulators in the coming year will center on whether industry-led transparency efforts are sufficient to protect patient access or if federal intervention will be required to standardize the use of AI in medical coverage decisions.